Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay
-
Published:2024-04-20
Issue:
Volume:
Page:
-
ISSN:1720-8386
-
Container-title:Journal of Endocrinological Investigation
-
language:en
-
Short-container-title:J Endocrinol Invest
Author:
De Vincentis S.ORCID, Greco C.ORCID, Fanelli F.ORCID, Decaroli M. C.ORCID, Diazzi C.ORCID, Mezzullo M.ORCID, Milic J., De Santis M. C.ORCID, Roli L.ORCID, Pagotto U.ORCID, Guaraldi G.ORCID, Rochira V.ORCID
Abstract
Abstract
Purpose
Sex steroids play a key role on male bone homeostasis and body composition (BC), their role in men living with HIV (MLWH) is less recognized. This study aimed at investigating the prevalence of low BMD, sarcopenia, and sarcopenic obesity (SO) and their relationship with sex steroids in MLWH aged < 50.
Methods
Prospective, cross-sectional, observational study on MLWH younger than 50 (median age 47.0 years). BC and BMD were evaluated with DXA. Two different definitions of sarcopenia were applied: appendicular lean mass/height2 (ALMI) < 7.26 kg/m2 or appendicular lean mass/body weight (ALM/W) < 28.27%. Low BMD was defined for Z-score < −2.0. Sarcopenia coupled with obesity identified SO. Serum total testosterone (T) and estradiol (E2) were measured by LC–MS/MS; free testosterone (cFT) was calculated by Vermeulen equation.
Results
Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) out of 307 MLWH according to ALMI and ALM/W, respectively. The prevalence of SO was similar by using both ALMI (11.4%) and ALM/W (12.4%). Sarcopenic and SO MLWH had lower total T and cFT in both the definition for sarcopenia. BMD was reduced in 43/307 (14.0%). Serum E2 < 18 pg/mL was an independent contributing factor for sarcopenia, SO, and low BMD.
Conclusions
T and E2 are important determinants of BC even in MLWH. This is among the first studies investigating the distribution of obesity phenotypes and the prevalence of SO among MLWH showing that SO is present in 11–12% of enrolled MLWH regardless of the definition used. However, deep differences emerged using two different diagnostic definitions.
Funder
Università degli Studi di Modena e Reggio Emilia
Publisher
Springer Science and Business Media LLC
Reference77 articles.
1. Guaraldi G, Milic J, Mussini C (2019) Aging with HIV. Curr HIV/AIDS Rep 16(6):475–481 2. Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K (2014) Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 210(8):1170–1179 3. Frank Tahvi D et al (2019) Global, regional, and national incidence, prevalence, and mortality of HIV,1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the global burden of diseases 2017. Injuries, and Risk Factors Study Lancet HIV 6(12):e831–e859 4. Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D’Arminio Monforte A, D’Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F (2023) Pillars of long-term antiretroviral therapy success. Pharmacol Res 196:106898 5. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11):1120–1126
|
|